Streetbeat News

Regulatory

MDGL

The American Association for the Study of Liver Diseases (AASLD) celebrates the FDA's approval of Madrigal Pharmaceuticals' resmetirom for MASH treatment. Resmetirom, a liver-directed therapy, is the first FDA-approved treatment specifically for Metabolic dysfunction-Associated Steatohepatitis (MASH), addressing a significant unmet need in liver disease management. This approval is seen as a major advancement in hepatology, offering new hope for patients with MASH, a condition characterized by liver inflammation and fibrosis due to fat accumulation.

Portfolio Pulse from Benzinga Newsdesk

March 14, 2024 | 2:03 pm

AAPL

Apple Inc. (AAPL) has been granted a patent for technology that could transform future iPhones and iPads by introducing displays and controls on the device's sides. This innovative approach aims to enhance user experience by eliminating physical buttons and utilizing the sides for reconfigurable screens, similar to the MacBook Pro's Touch Bar. The patent is part of Apple's ongoing efforts to explore new form factors and functionalities, including flexible devices with multiple cameras and technologies to improve user privacy and conceptualize rollable iPhones.

Portfolio Pulse from Rounak Jain

March 14, 2024 | 1:54 pm

NTRA

Natera, Inc. (NASDAQ:NTRA) has expressed support for the new KDIGO guideline, which recommends genetic testing for most chronic kidney disease (CKD) patients to identify the disease's cause. This guideline aligns with Natera's Renasight test, potentially leading to broader adoption. The guideline's endorsement is based on the RenaCARE study, which showed the diagnostic utility of Renasight in CKD patients. Over 55% of U.S. nephrologists have ordered the Renasight test, indicating significant clinical acceptance.

Portfolio Pulse from Benzinga Newsdesk

March 14, 2024 | 1:53 pm

SOLO

XOS

ElectraMeccanica Vehicles Corp. (NASDAQ:SOLO) is set to host a special meeting on March 20, 2024, to vote on a proposed combination with Xos, Inc. (NASDAQ:XOS). The meeting aims to get shareholder approval for the arrangement, which has been detailed in a joint proxy statement filed with the SEC. The Board of Directors unanimously recommends voting in favor of the proposal.

Portfolio Pulse from Benzinga Newsdesk

March 14, 2024 | 1:48 pm

APM

FSR

IMRX

PRST

SPRB

WIMI

U.S. stocks traded higher following the release of Producer Price Index (PPI) data, showing a 0.6% increase in February, surpassing expectations. Energy shares led gains, while real estate lagged. Notable movements included Presto Automation Inc. (PRST), Aptorum Group Limited (APM), and WiMi Hologram Cloud Inc. (WIMI) trading up, whereas Spruce Biosciences, Inc. (SPRB), Fisker Inc. (FSR), and Immuneering Corporation (IMRX) traded down.

Portfolio Pulse from Avi Kapoor

March 14, 2024 | 1:46 pm

CYTH

Cyclo Therapeutics, Inc. (NASDAQ:CYTH) announced the issuance of a U.S. patent for Trappsol Cyclo, aimed at treating early onset Alzheimer's disease. This development is part of the company's efforts to address the significant unmet need for therapeutic solutions in Alzheimer's treatment.

Portfolio Pulse from Benzinga Newsdesk

March 14, 2024 | 1:35 pm

ABVC

ABVC BioPharma, Inc. (NASDAQ:ABVC) announced its fiscal year 2024 Q1 business update, highlighting a licensing deal with AiBtl BioPharma Inc. for CNS drugs, regaining Nasdaq compliance, strategic investments in real estate for healthcare development, and various financial transactions including securities purchase agreements with Lind Global Fund II, LP. The company reported a decrease in revenues and operating expenses, a net loss reduction, and progress in R&D including patents, FDA approvals, and a licensing agreement with Xinnovation Therapeutics Co., Ltd for the Chinese market.

Portfolio Pulse from Benzinga Newsdesk

March 14, 2024 | 1:35 pm

INTC

SSNLF

TSM

Intel is reportedly in discussions to receive significant subsidies for its U.S. fab development, which would enhance its competitiveness against TSMC. Similarly, Samsung is continuing to receive financial support from the South Korean government, according to sources from fab toolmakers as reported by DigiTimes.

Portfolio Pulse from Benzinga Newsdesk

March 14, 2024 | 1:28 pm

BTCUSD

ETHUSD

SPY

Cryptocurrencies like Bitcoin, Ethereum, and Dogecoin show mixed trading signals, with Ethereum completing the 'Dencun' upgrade. Dogecoin's value may rise as Tesla considers accepting it for payments. Hacken's market cap reaches $57M after unveiling a tokenized share offering. Bitcoin critic Peter Schiff expresses regret over not investing in Bitcoin earlier. Crypto miners see record profits amid a Bitcoin rally. US markets see mixed movements with Hello Group and others moving lower. Political and global events include potential lawsuits, defense decisions, and tech partnerships. Electric vehicle market updates include Tesla's plans and competition from Polestar. Consumer, communication, healthcare, general news, space, and energy sectors also see significant updates.

Portfolio Pulse from Akanksha Bakshi

March 14, 2024 | 1:13 pm

GRI

GRI Bio, Inc. (NASDAQ:GRI) announced the Canadian Intellectual Property Office's notice of allowance for a patent covering NKT cell modulators for treating inflammatory, fibrotic, and autoimmune diseases. This development is part of GRI Bio's efforts to protect its innovative pipeline globally. The company is advancing its lead program, GRI-0621, for treating Idiopathic Pulmonary Fibrosis, with interim Phase 2a data expected in the first half of 2024.

Portfolio Pulse from Benzinga Newsdesk

March 14, 2024 | 1:02 pm